Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vuk Zdinjak

Psychedelic Treatment For Alcoholism? Clearmind Medicine And SciSparc Collaboration Yields Positive Results

Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, revealed positive safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

The trial evaluated the proprietary combination of Clearmind's proprietary psychedelic molecule MEAI and SciSparc's CannAmide for treating alcohol consumption.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.